Actinium Pharmaceuticals, Inc. (NYSE: ATNM)

Actinium Pharmaceuticals, Inc. (ATNM) is a biopharmaceutical company that operates within the healthcare industry, specifically focusing on the development of targeted radiotherapies to improve survival for patients with relapsed or refractory cancer. The company's primary vision is to establish itself as a specialty, hospital-focused, radiotherapeutics company, developing and marketing medicines for patients primarily treated in large quaternary care hospitals and their surrounding areas.

Actinium's main business activities involve the development and commercialization of product candidates, such as Iomab-B and Actimab-A. Iomab-B is an Antibody-Radioconjugate (ARC) that targets CD45, a protein expressed on immune cells, and is being developed as a bridging therapy for patients with relapsed or refractory acute myeloid leukemia (AML). Actimab-A is another ARC that targets CD33, a protein expressed on myeloid cells, and is being developed as a therapeutic agent for patients with AML. These product candidates are designed to provide a curative option for patients with AML and other blood cancers, thereby improving their quality of life and survival outcomes.

Within the industry, Actinium holds a unique position, with its product candidates having the potential to fill the major unmet medical needs in relapsed or refractory AML and other blood cancers. The company's competitive advantages include its focus on developing targeted radiotherapies, its ability to provide both disease control and conditioning in one agent, and its partnerships with leading cancer centers and institutions. Some of its key competitors within the industry include other biopharmaceutical companies developing treatments for cancer, although Actinium's targeted radiotherapy approach sets it apart.

Although the text does not provide specific names of customers, it does mention that the company's product candidates are designed for patients with relapsed or refractory cancer, as well as the hospitals and cancer centers that treat them. Therefore, the customers of Actinium Pharmaceuticals are primarily hospitals, cancer centers, and patients suffering from relapsed or refractory cancer.

In terms of its product portfolio, Actinium has developed several brand names and trade names for its products and services. These include Iomab-B, Actimab-A, and Iomab-ACT. Each of these product candidates has demonstrated promising results in clinical trials and is an essential part of the company's growth strategy.